Related Experiment Video
Updated: Aug 8, 2026

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
Spotlight on rasburicase in anticancer therapy-induced hyperuricemia
Vicki Oldfield1, Caroline M Perry
1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
Rasburicase is a recombinant uricolytic agent effective for managing anticancer therapy-induced hyperuricemia in pediatric and adult patients. It offers a quicker therapeutic response and is cost-effective, though potential adverse events require careful consideration.
Area of Science:
- Oncology
- Pharmacology
- Nephrology
Background:
- Anticancer therapy can induce hyperuricemia, a condition requiring management.
- Rasburicase is the first recombinant uricolytic agent available for treating hyperuricemia.
- Hyperuricemia poses risks, particularly in pediatric and adult patients undergoing cancer treatment.
Purpose of the Study:
- To evaluate the efficacy and tolerability of rasburicase in managing anticancer therapy-induced hyperuricemia.
- To compare rasburicase with allopurinol in pediatric patients.
- To assess the cost-effectiveness of rasburicase for hyperuricemia prevention and treatment.
Main Methods:
- Intravenous administration of rasburicase.
- Clinical assessment of therapeutic response and adverse events.
- Pharmacoeconomic analysis comparing rasburicase and allopurinol.
Main Results:
- Rasburicase is effective and generally well-tolerated in both pediatric and adult patients.
- Significantly reduced systemic uric acid exposure and quicker response compared to allopurinol in pediatrics.
- Rasburicase demonstrated cost-effectiveness in preventing hyperuricemia in children and treating it in adults.
Conclusions:
- Rasburicase is a valuable option for prophylaxis and treatment of anticancer therapy-induced hyperuricemia in pediatric and adult populations.
- Potential serious hematologic adverse events and hypersensitivity reactions necessitate careful patient monitoring.
- Further studies are needed to compare rasburicase and allopurinol efficacy in adult patients.
More Related Videos
06:21Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
10:02Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
Published on: October 3, 2020
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drugs that Destabilize Microtubules
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...